Abstract
In August 2011 vemurafenib (Zelboraf; Daiichi Sankyo/Roche), an inhibitor of BRAF kinase, was approved by the US Food and Drug Administration (FDA) for the treatment of patients with unresectable or metastatic melanoma with the BRAFV600E mutation.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Physio-pathological effects of m6A modification and its potential contribution to melanoma
Clinical and Translational Oncology Open Access 08 June 2021
-
Genetic and Epigenetic Alterations of TERT Are Associated with Inferior Outcome in Adolescent and Young Adult Patients with Melanoma
Scientific Reports Open Access 05 April 2017
-
Nifuroxazide exerts potent anti-tumor and anti-metastasis activity in melanoma
Scientific Reports Open Access 02 February 2016
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Garbe, C. et al. Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist 16, 5–24 (2011).
Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711–723 (2010).
Davies, H. et al. Mutations of the BRAF gene in human cancer. Nature 417, 949–954 (2002).
Tsai, J. et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc. Natl Acad. Sci. USA 105, 3041–3046 (2008).
Bollag, G. et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467, 596–599 (2010).
US Food and Drug Administration. FDA labeling information — Zelboraf. FDA website [online], (2011).
Flaherty, K. T. et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809–819 (2010).
Chapman, P. B. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507–2516 (2011).
Boni, A. et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res. 70, 5213–5219 (2010).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
Keith Flaherty has served on the scientific advisory board for Genentech/Roche.
Rights and permissions
About this article
Cite this article
Flaherty, K., Yasothan, U. & Kirkpatrick, P. Vemurafenib. Nat Rev Drug Discov 10, 811–812 (2011). https://doi.org/10.1038/nrd3579
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd3579
This article is cited by
-
Computational biophysics approach towards the discovery of multi-kinase blockers for the management of MAPK pathway dysregulation
Molecular Diversity (2023)
-
Physio-pathological effects of m6A modification and its potential contribution to melanoma
Clinical and Translational Oncology (2021)
-
Docking-based structural splicing and reassembly strategy to develop novel deazapurine derivatives as potent B-RafV600E inhibitors
Acta Pharmacologica Sinica (2017)
-
Genetic and Epigenetic Alterations of TERT Are Associated with Inferior Outcome in Adolescent and Young Adult Patients with Melanoma
Scientific Reports (2017)
-
Nifuroxazide exerts potent anti-tumor and anti-metastasis activity in melanoma
Scientific Reports (2016)
